Carnegie Mellon researchers have used FRESH 3D bioprinting to create the first collagen-based microphysiologic systems, ...

Vivani’s emerging pipeline also includes NPM-119, which refers to the Company’s six-month, subdermal, GLP-1 (exenatide ...

Vivani's emerging pipeline also includes NPM-119, which refers to the Company's six-month, subdermal, GLP-1 (exenatide implant) under development for the treatment of type 2 diabetes. Development of a ...

Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc.

"Currently, Medicare covers these drugs only under specific circumstances, such as for diabetes or heightened heart risk," he wrote. "And Medicaid coverage is even more limited." Fetterman added ...

Gymnema is a complementary treatment for type 1 and type 2 diabetes. While it isn’t a replacement for insulin, it may aid in blood sugar regulation. Gymnema is a woody climbing shrub from the ...

A new study published in JAMA Neurology finds that people with type 2 diabetes who take two common anti-diabetes medications have a reduced risk of Alzheimer’s and associated dementias.

(CNN) — The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on ...

But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can’t make enough of their own ...

Now, a major study published in JAMA Neurology reveals that certain medications used to treat type 2 diabetes might offer significant protection against Alzheimer’s disease and other forms of ...